Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price3.10 USD
Fair value5.67
Ethical score70.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-26Read Markup3.91-20.7% to today Distribution gives way to Markup first Markup read since October
2026-10-18Read Distribution3.91-20.7% to today ✓Markup gives way to Distribution first Distribution read since October
2026-10-11Read Markup3.85-19.5% to today Distribution gives way to Markup after a 16% slide in 3 weeks
2026-09-21Read Distribution4.58-32.3% to today ✓Markup gives way to Distribution first Distribution read since July
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
eXp World Holdings, Inc. holds its Distribution at $3.10. The statistical read favours the sellers, held for 8 days.
As held on the ledger · 2026-11-06
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 8 days
Price at the screen
$3.10
Valuation
N/A trailing · 11.00 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.06
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
52.68%
Below 49%
Money owed to the company is 52.7% of assets, above the 49% limit.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
eXp World Holdings,'s business is fine, but its receivables are about 53% of its assets, just over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AGNT's ethical verdict changes
Today AGNT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 31% discount to our $5.67 fair value, 5.30% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 45.3% discount to the base estimate.
Where our models see it going: fair-value estimate $5.67, with a range of $5.67 to $6.53, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it stands out
A 5%-growth business trading at just 11.0x forward earnings. That is a 31% discount to our $5.67 fair value: the market is pricing it cautiously while the fundamentals argue otherwise.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AGNT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$4.27+8.9%Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markup$3.92+1.0%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$3.88+0.0%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$3.88+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$3.88-2.5%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$3.98+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$3.98+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$3.98+1.8%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup · changed$3.91+0.0%Entry 11
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $9.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $9.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.